Review: Nutritional Senotherapeutics for Brain Aging and Neurodegeneration
This review describes how senescent brain cells and their secreted signals contribute to brain aging and neurodegenerative disease, and discusses nutritional senolytics and senomorphics as complementary strategies whose human evidence remains limited. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that senescent cells accumulate in multiple brain cell populations and secrete the senescence-associated secretory phenotype. [1]
According to the review, this secretion promotes chronic neuroinflammation, mitochondrial dysfunction, blood-brain barrier disruption and progressive neuronal damage. [1]
The review describes nutritional senotherapeutics as promising complementary strategies, but says clinical translation is constrained by limited human evidence, low bioavailability and unresolved dosing and blood-brain barrier questions. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Brain cell populations in brain aging and neurodegenerative diseases, as described in the review
- Summary based on
- Study abstract
- Original publication
- August 3, 2026
Senescent brain cells and secreted signals
The review states that cellular senescence is a key contributor to brain aging and neurodegenerative diseases, whose prevalence rises with life expectancy. Senescent cells accumulate in multiple brain cell populations and secrete the senescence-associated secretory phenotype (SASP). According to the review, this promotes chronic neuroinflammation, mitochondrial dysfunction, blood-brain barrier disruption and progressive neuronal damage.
Supporting source [1]
Nutritional senolytics versus senomorphics
The review discusses senotherapeutics that either eliminate senescent cells (senolytics) or modulate the SASP (senomorphics), with emphasis on naturally occurring bioactive compounds from dietary sources that target molecular pathways of cellular senescence. It states that senomorphic compounds such as sulforaphane, curcumin and resveratrol primarily attenuate oxidative stress and inflammatory signaling, whereas senolytic agents including quercetin and fisetin selectively promote elimination of senescent cells by disrupting pro-survival pathways.
Supporting source [1]
Limited human evidence and translation barriers
The review reports that current evidence comes from experimental models and emerging clinical studies, and describes nutritional senotherapeutics as promising complementary strategies for modulating cellular senescence and promoting brain health. It states that clinical translation remains constrained by limited human evidence, low bioavailability and unresolved questions about optimal dosing and blood-brain barrier penetration, and that well-designed clinical trials are needed before the therapeutic potential can be fully established.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no sample sizes, follow-up periods or effect estimates, and the evidence it cites comes from experimental models and emerging clinical studies. The compounds are discussed as research strategies, not as established human treatments.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Salas-Venegas V, López-Diazguerrero NE, Ramírez-Carreto RJ, Konigsberg M, Chavarría A. · europepmc.org · August 3, 2026